NIH #R01CA287734
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
Active
- Amount
- $600K–$700K
- Period
- 2024-08-01 → 2029-07-31
- PIs
- 2
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR